188 related articles for article (PubMed ID: 33607457)
1. Synthesis and evaluation of cyclopentane-based muraymycin analogs targeting MraY.
Kwak SH; Lim WY; Hao A; Mashalidis EH; Kwon DY; Jeong P; Kim MJ; Lee SY; Hong J
Eur J Med Chem; 2021 Apr; 215():113272. PubMed ID: 33607457
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Medicinal Chemistry of Muraymycins, Nucleoside Antibiotics.
Katsuyama A; Ichikawa S
Chem Pharm Bull (Tokyo); 2018; 66(2):123-131. PubMed ID: 29386462
[TBL] [Abstract][Full Text] [Related]
3. Structural insights into inhibition of lipid I production in bacterial cell wall synthesis.
Chung BC; Mashalidis EH; Tanino T; Kim M; Matsuda A; Hong J; Ichikawa S; Lee SY
Nature; 2016 May; 533(7604):557-560. PubMed ID: 27088606
[TBL] [Abstract][Full Text] [Related]
4. Structures of Bacterial MraY and Human GPT Provide Insights into Rational Antibiotic Design.
Mashalidis EH; Lee SY
J Mol Biol; 2020 Aug; 432(18):4946-4963. PubMed ID: 32199982
[TBL] [Abstract][Full Text] [Related]
5. Muraymycin Nucleoside Antibiotics: Structure-Activity Relationship for Variations in the Nucleoside Unit.
Heib A; Niro G; Weck SC; Koppermann S; Ducho C
Molecules; 2019 Dec; 25(1):. PubMed ID: 31861655
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of action of nucleoside antibacterial natural product antibiotics.
Bugg TDH; Kerr RV
J Antibiot (Tokyo); 2019 Dec; 72(12):865-876. PubMed ID: 31471595
[TBL] [Abstract][Full Text] [Related]
7. Caprazamycins: Promising lead structures acting on a novel antibacterial target MraY.
Patel B; Ryan P; Makwana V; Zunk M; Rudrawar S; Grant G
Eur J Med Chem; 2019 Jun; 171():462-474. PubMed ID: 30933853
[TBL] [Abstract][Full Text] [Related]
8. Insights into the Target Interaction of Naturally Occurring Muraymycin Nucleoside Antibiotics.
Koppermann S; Cui Z; Fischer PD; Wang X; Ludwig J; Thorson JS; Van Lanen SG; Ducho C
ChemMedChem; 2018 Apr; 13(8):779-784. PubMed ID: 29438582
[TBL] [Abstract][Full Text] [Related]
9. Merging Natural Products: Muraymycin-Sansanmycin Hybrid Structures as Novel Scaffolds for Potential Antibacterial Agents.
Niro G; Weck SC; Ducho C
Chemistry; 2020 Dec; 26(70):16875-16887. PubMed ID: 32897546
[TBL] [Abstract][Full Text] [Related]
10. Simplified Novel Muraymycin Analogues; using a Serine Template Strategy for Linking Key Pharmacophores.
Patel B; Kerr RV; Malde AK; Zunk M; Bugg TDH; Grant G; Rudrawar S
ChemMedChem; 2020 Aug; 15(15):1429-1438. PubMed ID: 32476294
[TBL] [Abstract][Full Text] [Related]
11. Aminoribosylated Analogues of Muraymycin Nucleoside Antibiotics.
Wiegmann D; Koppermann S; Ducho C
Molecules; 2018 Nov; 23(12):. PubMed ID: 30486316
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for selective inhibition of antibacterial target MraY, a membrane-bound enzyme involved in peptidoglycan synthesis.
Hering J; Dunevall E; Ek M; Brändén G
Drug Discov Today; 2018 Jul; 23(7):1426-1435. PubMed ID: 29778697
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of phospho-MurNAc-pentapeptide translocase (MraY) by nucleoside natural product antibiotics, bacteriophage ϕX174 lysis protein E, and cationic antibacterial peptides.
Bugg TD; Rodolis MT; Mihalyi A; Jamshidi S
Bioorg Med Chem; 2016 Dec; 24(24):6340-6347. PubMed ID: 27021004
[TBL] [Abstract][Full Text] [Related]
14. Chemical logic of MraY inhibition by antibacterial nucleoside natural products.
Mashalidis EH; Kaeser B; Terasawa Y; Katsuyama A; Kwon DY; Lee K; Hong J; Ichikawa S; Lee SY
Nat Commun; 2019 Jul; 10(1):2917. PubMed ID: 31266949
[TBL] [Abstract][Full Text] [Related]
15. Elucidating the Structural Requirement of Uridylpeptide Antibiotics for Antibacterial Activity.
Terasawa Y; Sataka C; Sato T; Yamamoto K; Fukushima Y; Nakajima C; Suzuki Y; Katsuyama A; Matsumaru T; Yakushiji F; Yokota SI; Ichikawa S
J Med Chem; 2020 Sep; 63(17):9803-9827. PubMed ID: 32787111
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel inhibitors of phospho-MurNAc-pentapeptide translocase MraY from library screening: Isoquinoline alkaloid michellamine B and xanthene dye phloxine B.
Mihalyi A; Jamshidi S; Slikas J; Bugg TD
Bioorg Med Chem; 2014 Sep; 22(17):4566-71. PubMed ID: 25127465
[TBL] [Abstract][Full Text] [Related]
17. Caprazamycins: Biosynthesis and structure activity relationship studies.
Wiker F; Hauck N; Grond S; Gust B
Int J Med Microbiol; 2019 Jul; 309(5):319-324. PubMed ID: 31138496
[TBL] [Abstract][Full Text] [Related]
18. Antibacterial Nucleoside Natural Products Inhibiting Phospho-MurNAc-Pentapeptide Translocase; Chemistry and Structure-Activity Relationship.
Ichikawa S; Yamaguchi M; Matsuda A
Curr Med Chem; 2015; 22(34):3951-79. PubMed ID: 26282943
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic analysis of muraymycin analogues: a guide to the design of MraY inhibitors.
Tanino T; Al-Dabbagh B; Mengin-Lecreulx D; Bouhss A; Oyama H; Ichikawa S; Matsuda A
J Med Chem; 2011 Dec; 54(24):8421-39. PubMed ID: 22085339
[TBL] [Abstract][Full Text] [Related]
20. Phospho-MurNAc-pentapeptide translocase (MraY) as a target for antibacterial agents and antibacterial proteins.
Bugg TD; Lloyd AJ; Roper DI
Infect Disord Drug Targets; 2006 Jun; 6(2):85-106. PubMed ID: 16789873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
